Boehringer Ingelheim and MiNA Therapeutics to develop liver disease therapies

Boehringer Ingelheim has announced a new partnership with MiNA Therapeutics that will focus on the development of innovative treatments for liver disease.

Under the terms of the agreement, the companies will create a series of novel compounds to treat fibrotic liver diseases such as nonalcoholic steatohepatitis (NASH), based on MiNA's small activating RNA (saRNA) therapeutics platform.

This new partnership will combine MiNA's expertise in the development of saRNAs with Boehringer Ingelheim's experience in developing first-in-class breakthrough treatments for patients with cardiometabolic disease.

Previous studies have shown that saRNA therapies can activate the transcription of specific genes, resulting in the upregulation of proteins with therapeutic potential. Boehringer Ingelheim and MiNA will therefore be looking to identify targets that can restore the metabolic functionality of hepatocytes and prevent fibrotic tissue formation in patients with NASH.

Dr Clive Wood, corporate senior vice-president for discovery research at Boehringer Ingelheim, said: "This new collaboration is another sign of our ongoing commitment to patients with cardiometabolic diseases, including NASH. It will combine MiNA's pioneering work with saRNAs with our expertise in biopharmaceutical research and development."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.